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Abstract 
Inflammatory disorders like diabetes, systemic lupus erythematodes, inflammatory lung diseases, rheumatoid arthritis 
and multiple sclerosis, but also rejection of transplanted organs and GvHD, form a major burden of disease. Cur-
rent classes of immune suppressive drugs to treat these disorders are never curative and side effects are common. 
Therefore there is a need for new drugs with improved and more targeted modes of action. Potential candidates 
are the DNA methyl transferase inhibitor 5-azacytidine (Aza) and its derivative 5-aza 2′deoxycitidine (DAC). Aza and 
DAC have been tested in several pre-clinical in vivo studies. In order to obtain an overview of disorders for which Aza 
and/or DAC can be a potential treatment, and to find out where information is lacking, we systematically reviewed 
pre-clinical animal studies assessing Aza or DAC as a potential therapy for distinct inflammatory disorders. Also, study 
quality and risk of bias was systematically assessed. In the 35 identified studies, we show that both Aza and DAC do 
not only seem to be able to alleviate a number of inflammatory disorders, but also prevent solid organ rejection and 
GvHD in in vivo pre-clinical animal models. Aza/DAC are known to upregulate FOXP3, a master transcription factor for 
Treg, in vitro. Seventeen studies described the effect on Treg, of which 16 studies showed an increase in Treg. Increas-
ing Treg therefore seems to be a common mechanism in preventing inflammatory disorders by Aza/DAC. We also 
found, however, that many essential methodological details were poorly reported leading to an unclear risk of bias. 
Therefore, reported effects might be an overestimation of the true effect.
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Background
Epigenetic mechanisms such as (de)methylation of DNA/
RNA are important for the development and function 
of the immune system. A failure to maintain epigenetic 
homeostasis may lead to aberrant gene expression, and 
contribute to immune dysfunction including the devel-
opment of autoimmunity and autoinflammatory disor-
ders [1]. Epigenetic modifiers are studied as potent drugs 
to regulate the immune system [2]. A drug with much 
potential is 5-azacytidine (Aza, Vidaza) and its deriva-
tive 5-Aza-2′-deoxycytidine (DAC, Decitabine)[2]. Aza 
and DAC are cytidine analogs which are incorporated 
into DNA/RNA and DNA respectively [3]. Incorporation 
of Aza/DAC leads to inactivation of DNA methyltrans-
ferases (DNMT), thereby leading to hypomethylation of 
DNA. Genes are silenced by hypermethylation, therefore 
demethylation leads to increased gene expression [4]. 
In high concentrations, Aza and DAC are cytotoxic to 
abnormal hematopoietic cells [3].
Currently, Aza and DAC are used as a treatment 
for hematological malignancies, including myelod-
ysplastic syndrome (MDS) and acute myeloid leuke-
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option, mainly in elderly patients [5, 6]. The anticancer 
effect is thought to depend on promoting anti-tumor 
genes by hypomethylation and direct cytotoxic effects 
to abnormal hematopoietic cells [7, 8]. In MDS and 
AML patients, upon Aza treatment, changes in CD4 + , 
CD8 + and Treg numbers were found [9].
Treg are anti-inflammatory cells and important for 
the homeostasis of the immune system. Stability of 
Treg is controlled by stable expression of the transcrip-
tion factor Forkhead Box P3 (FOXP3) [10, 11]. In vitro, 
Tconv and Treg were shown to further upregulate 
FOXP3 upon cell stimulation in the presence of Aza/
DAC, which is explained by hypomethylation of the 
Treg-specific demethylated region (TSDR) within the 
FOXP3 gene [12, 13]. Immune-disturbances of Treg 
in auto-immune/auto-inflammatory disorders such 
as diabetes, psoriasis and in graft versus host disease 
(GvHD) cause a shift to a pro-inflammatory response 
[14]. Upregulating Treg or promoting Treg stability via 
epigenetic modification is therefore a promising new 
treatment option [2].
Because of the promising in vitro results, Aza and DAC 
are also being studied in animal models of auto-immune 
and auto-inflammatory disorders. These in  vivo studies 
vary widely in disease-, drug regimen- and cells stud-
ied as outcome. Combining and comparing all different 
in vivo animal studies may lead to new insights regarding 
the use of Aza/DAC in clinical disease. It may also lead 
to a reduction and refinement of animals used, because 
of design of improved study protocols. We therefore sys-
tematically reviewed the existing literature on Aza and 
DAC used as treatment in animal models of inflamma-
tory disorders to study its effect on the immune system. 
This systematic review contains: a complete overview of 
animal studies on this topic based on a comprehensive 
search strategy, an overview of clinical outcomes of all 
selected studies, summarized evidence for the effect of 
treatment of inflammatory disorders with Aza and DAC 
on immune outcomes, and an assessment of the risk of 
bias and reporting quality of the selected animal studies.
Methods
Review protocol
This systematic review investigates the effect of azacyti-
dine (Aza) and decitabine (DAC) on immune-related out-
comes in animal models for inflammatory disorders. The 
inclusion and exclusion criteria and method of analysis 
were specified in advance and documented in a protocol 
registered on PROSPERO (https ://www.crd.york.ac.uk/
prosp ero) with registration number CRD42018088017 on 
26-02-2018. The protocol is based on the protocol format 
from SYRCLE (https ://www.syrcl e.nl) [15].
Search strategy and selection of relevant studies
A comprehensive search string to identify studies assess-
ing the use of Aza or DAC as a treatment for inflam-
matory disorders in an animal model was generated. 
The databases Pubmed and Embase were used to find 
all primary studies (date last search: 27-09-2019). The 
search strategy consisted of three search components: 
Aza or DAC, inflammatory disorders and animal studies. 
The search strategies can be found in Additional file  1: 
Table S1. The search filters for animal studies for Embase 
and Pubmed were used from SYRCLE [16, 17].
The studies found by the search strategy of both Pub-
med and Embase were combined and cleared of dupli-
cations. Papers were screened by two independent 
investigators (SL and CvdH) with the use of Early Review 
Organizing Software (EROS; Institute of Clinical Effec-
tiveness and Health Policy, Buenos Aires, Argentina). 
Studies were included when Aza or DAC was used in an 
animal model for an inflammatory disease with immune 
outcomes. Inflammatory disorders were defined as 
non-infectious inflammation including auto-immune 
and auto-inflammatory disorders, organ rejection after 
transplantation and GvHD. Studies were excluded when: 
Aza or DAC was not used, no inflammatory disease was 
studied, the study did not contain an animal model, the 
study was not a primary study (for example a review or 
conference abstract) or the study had no immune out-
comes. Disorders were excluded when bacterial or viral 
infections were used without the purpose of inducing an 
inflammatory disease. Also cancer, myocardial infarction, 
fibrosis and sickle cell anemia were excluded because we 
did not consider them as an inflammatory disease even 
though they have inflammatory components. No restric-
tions on language were used both during the search and 
selection.
The first selection of relevant studies was done based 
on the abstract and title by two independent reviewers 
(SL and CvdH). In case of doubt whether a study should 
be included the whole article was evaluated. In case of 
differences between both investigators a third investiga-
tor was consulted (PvE). After the first selection, a second 
selection was done based on the whole article. The same 
inclusion and exclusion criteria were used and in case of 
differences a third investigator was consulted.
Data extraction and synthesis
The following characteristic were extracted from the 
studies by two independent investigators (SL and CvdH): 
study design (control group used, experimental group 
used, group size), animal model characteristics (animal 
species, sex), disease model used (modeled disease, type 
of induction of the disease), intervention characteristics 
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(Aza or DAC used, dose of drug used, dose regimen used, 
route of administration) and clinical outcome. In case of 
discrepancies, the investigators discussed the study and 
found agreement.
Induction of Treg upon Aza/DAC treatment is a com-
mon hypothesis for the immune modulatory effect these 
drugs. Therefore we summarized the effect of Aza/DAC 
treatment on FOXP3/Treg cells. Because the number of 
studies per inflammatory disease was too low and the 
heterogeneity in characteristics between the studies was 
too high, we decided not to combine the outcome data in 
a meta-analysis. Instead, we created a table displaying the 
direction of effect as reported by the authors per immune 
outcome. An overview was made of significant changes 
in the immune cell populations of leukocytes (CD45), 
granulocytes, lymphocytes, macrophages, T cells (CD3), 
T-helper cells (CD4), cytotoxic T cells (CD8) and B cells 
(B220). We also made an overview of the commonly 
measured cytokines IL-1β, IL-4, IL-5, IL-6, IL-10, IL-12, 
IL-13, IL-17, TNFα, TGFβ and IFNγ.
Quality assessment
SYRCLE Risk of bias (RoB) tool was used to assess the 
risk of bias in the included studies [18]. A ‘yes’ score 
indicates low risk of bias; a ‘no’ score indicates a high 
risk of bias; and a ‘?’ score indicates unclear risk of bias. 
Because the reporting of experimental details on animals, 
methods and materials tends to be very poor, we added 
a few items on the quality of reporting: reporting of: any 
blinding, any randomization, any housing conditions, 
ethical approval and any conflict of interest. Two inde-
pendent reviewers (SL and CvdH) assessed the RoB and 
reporting quality in all included studies.
Results
Study selection
Searching Pubmed and Embase for references regard-
ing Aza and DAC on immune-related outcomes in ani-
mal models for inflammatory disorders resulted in 1747 
references. Removal of duplicates left 1427 papers for 
screening based on abstract and title. 125 studies passed 
the abstract and title screening, of which 35 studies were 
left after full text screening. Figure 1 shows the PRISMA 
chart of the study selection process.
Study characteristics
In the 35 studies included, Aza was used 18 times and 





















1747 records idenfied through database 
searching in Pubmed and Embase
1428 records aer removal of duplicates
1747 records screened on abstract and tle 1302 excluded by tle and abstract
125 records screened on full-text 90 full text records excluded
No inflammatory disease: 20
Not a primary study: 49
Not an animal model: 4
No Azacydine or Decitabine: 11
No immune outcomes: 635 studies included
Fig. 1 PRISMA chart of study selection process. Duplicate references are references that are mentioned in multiple medical databases (e.g. same 
references in Embase and Pubmed) or studies published in duplicate (e.g. same study in multiple journals)
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and DAC were used. Most studies described the dose 
as grams per kg. Doses of Aza used varied from 0.15 to 
25  mg/kg. Doses of studies describing the dose in μg/
dose varied from 10 to 100 μg. It was unfortunately not 
possible to convert this dose to mg/kg. One study used 
nanolipogels to specifically target CD4 + or CD8 + T 
cells. This study used a dose of 5 μg/dose. Doses of DAC 
used varied from 0.1 to 20  mg/kg. One study treated 
cells ex  vivo with 0.5  μM DAC before infusion of cells. 
Drugs were administered intraperitoneally (28 times), 
intravenously (2 times) or subcutaneously (3 times). In 
three studies, the route of administration was not well 
described. Thirty-one studies used mice, 1 used rats, 2 
used both mice and rats, and 1 study used chickens. Six-
teen studies used male animals, while 6 used female ani-
mals; use of both sexes was reported in 6 cases, while in 
6 studies sex was not mentioned. One study mentioned 
that they used cells from male mice for in  vitro stud-
ies, but it was unclear whether this was also the case for 
the in  vivo studies. Study characteristics are shown in 
Table 1.
Study quality and risk of bias
Results on risk of bias and on reporting of quality indica-
tors are shown in Figs. 2 and 3, respectively. Scores per 
individual study can be found in Additional file  2: Fig-
ure S1. In 8 (23%) of the studies experiments were ran-
domized in some way. However details regarding the 
procedure of randomization were not reported in any 
publication. This resulted in an unclear risk of bias for 
random allocation, random housing and randomization 
of outcome assessment. Any blinding of experiments 
was reported in 6 of the studies. Four of those reported 
blinded outcome assessment, which resulted in a low 
risk of bias. No blinding of group allocation or caregiv-
ers was reported, leading to an unclear risk of bias. One 
study scored a high risk of bias on blinding of the caregiv-
ers (performance bias), because it was stated that control 
animals did not receive any injections while experimen-
tal animals did. Baseline characteristics were properly 
reported and seemed comparable between groups in 9 
studies, resulting in a low risk of bias for selection bias. 
The remaining studies did not report baseline character-
istics and were therefore assigned an unclear risk of bias. 
Attrition bias was unclear in 20 of the studies: in these 
studies information about dropouts and animals used per 
group was reported insufficiently. In 14 cases informa-
tion about drop-outs and number of animals used was 
properly mentioned, and no big differences in drop-outs 
between groups were seen, and the risk of attrition bias 
was therefore judged as low. In one publication a high 
risk of bias for attrition was scored because the number 
of animals used in total was not mentioned properly, 
while at the same time animals used varied a lot between 
experiments, which could indicate unreported drop-
outs. Sample size calculation was only mentioned once. 
Any statement about housing of animals was included in 
10 studies. Ethical approval was reported 28 times. Any 




From the 35 included studies, 7 studied GvHD [19–25]. 
One of these studies also described organ rejection [19]. 
Five other studies also described organ rejection [26–30] 
of which one was addressed islet transplantation for the 
treatment of diabetes [30]. Since this study did not dis-
cuss the effect on the diabetes itself, we categorized it 
under ‘transplantation’. Organ or stem cell transplanta-
tion can be a lifesaving treatment for patients with organ 
failure or hematological malignancies. Major risks of 
transplantation are graft versus host disease (GvHD) and 
organ rejection [31, 32]. T-cells play a major role in both 
GvHD and organ rejection, and immune suppression is 
largely directed at dampening this type of response [33]. 
Most studies showed an improved outcome upon Aza or 
DAC treatment (Table 1), i.e. GvHD was decreased, and 
Aza/DAC prolonged graft survival in 4 out of 6 studies. 
In the other 2 studies, only a combination of Aza and 
another treatment led to prolonged survival.
Five studies described the effect of Aza/DAC on diabe-
tes [34–38]. T1DM is characterized by the lack of insu-
lin production in the pancreas. T1DM can be modeled 
in mice by inducing diabetes using streptozotocin (STZ) 
in C57BL/6 mice [30] or by accelerating the spontane-
ous occurrence of diabetes in non-obese diabetic (NOD) 
mice using cyclophosphamide (CY-NOD) [34]. The stud-
ies on diabetes had very divergent outcome measures, 
but had in common that 4 out of 5 studies improved 
clinical outcome. One study only showed improvement 
in combination with another drug.
Like diabetes, atherosclerosis is a consequence of obe-
sity. Macrophage inflammation plays an important role 
in the atherosclerotic plaque formation, progression 
and rupture of the arteries [39]. One article described 
the effect of DAC on atherosclerosis [39] and showed 
reduced inflammation upon DAC treatment. One study 
described the effect of DAC of biliary arthresia, an auto-
immune disease seen after viral infection of the liver soon 
after birth, and showed alleviation of the disease [40].
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease characterized by the production of 
autoantibodies. Antibodies can be directed to all tissues 
and organs, but skin, joints, mucosa and kidneys are most 
often affected. The loss of self-tolerance is characterized 
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by autoreactive T and B cells producing autoantibodies 
and causing tissue injury [41]. Several studies were found 
in which Aza was used to induce SLE [42, 43], but also 3 
studies were found in which Aza was used as a potential 
treatment for SLE [44–46]. In these studies, Aza treat-
ment resulted in increased survival and improved clinical 
outcome.
Like the induction of lupus in mice, chronic low-dose 
administration of Aza in chickens is known to induce 
auto-immune thyroiditis [47]. This was the only study 
in which a species other than mice or rats was used. The 
outcome was dependent on the strain. In one strain, viti-
ligo was prevented, while in the other strain no effect was 
seen.
Respiratory tract inflammatory conditions are wide-
spread in the world. Respiratory tract inflammation is 
divided into acute and chronic respiratory inflamma-
tion. Acute inflammation includes pneumonia and acute 
respiratory distress syndrome (ARDS). The latter is an 
inflammatory disease initiated by a wide variety of both 
systemic (eg. sepsis) and pulmonary insults and leads to 
overwhelming inflammation in lung tissue [48]. Chronic 
respiratory tract inflammation includes (allergic) asthma 
and COPD. Asthma is a condition with chronic inflamed 
and narrowed airways and is triggered by allergies, cold, 
smoke, exercise and respiratory infections [49]. ARDS 
[50–54] and asthma [55, 56] were studied in 5 and 2 stud-
ies, respectively. In ARDS, 3 studies found alleviated lung 
injury. The 2 studies from Thangavel et al. only found an 
increase in survival when Aza was combined with other 
treatments. Both Aza and DAC decreased airway hyper-
sensitivity in the 2 studies in asthma.
Rheumatoid arthritis (RA) is a systemic autoimmune 
disease with chronic inflammation of the membrane 
(synovium) that lines the joints which leads to destruc-
tion of the connective tissues like cartilage, tendons and 
bone. Treatment of RA consists of slowing down the 
degradation process and pain relief, but there is no cure 
[57]. There were two studies on RA and Aza [58, 59]. In 
1 study Aza seemed to improve the clinical outcome, 
however no statistical analysis was performed. One study 
showed improved clinical outcome.
Multiple sclerosis (MS) and Guillain–Barré syndrome 
(GBS) are inflammatory autoimmune diseases causing 
demyelination of the nervous system. MS is a chronic 
disease affecting the central nervous system, while GBS 
can resolve over time and affects the peripheral nervous 
system [60, 61]. The effect of Aza in MS [28, 62, 63] and 
Fig. 2 Reporting of Risk of Bias assessment of the included studies. The exact questions The following questions were asked: (1) Was the 
allocation sequence adequately generated and applied? (2) Were the groups similar at baseline or adjusted for confounders? (3) Was the allocation 
adequately concealed? (4) Were the animals randomly housed during the experiment? (5) Were the caregivers /investigators during the course 
of the experiment adequately blinded? (6) Were the animals selected at random during outcome assessment? (7) Was the outcome assessment 
adequately blinded? (8) Were incomplete data outcome adequately addressed? By reporting “yes” we indicated the study as low risk of bias, “no” as 
high risk of bias, and “unclear” as not reported
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GBS [64] were examined in 3 and 1 studies, respectively. 
For MS all studies showed protection against experi-
mental MS upon treatment with Aza/DAC. Two out of 
3 studies showed that this was both the case employing a 
prevention as well as a treatment protocol. This was also 
the case for the study on GBS.
Specific cell subsets and cytokines
Since Aza/DAC are used to treat inflammatory disorders, 
we wanted to know what the effect of these drugs was 
on different immune cell subsets and relevant cytokines. 
Aza/DAC is known to upregulate FOXP3, therefore spe-
cial attention was given to the effect on Treg. Twenty-
three studies described one or more cell subsets of which 
17 studies reported on the effect of Aza/DAC on Treg 
(see Table 2).
All studies about GvHD and organ rejection showed 
an increase in Treg populations when mice were treated 
with Aza or DAC. In the study by Sanchez-Abarca et al., 
this was only the case with repeated dosing of Aza [21]. 
Also in the metabolic diseases diabetes and BA, Treg 
was increased upon Aza/DAC treatment. One study on 
SLE measured Treg, and showed an increase upon Aza 
treatment. In the lung diseases ARDS and asthma, the 
effect on Treg was measured in 2 studies; both found an 
increase in Treg. In all studies about neuroinflamma-
tory diseases (MS, GBS) Treg were studied. Three stud-
ies found an increase in Treg, but 1 study showed equal 
percentages after DAC treatment and lowered absolute 
numbers of Treg.
Other cell subsets that are studied varied widely over 
the different studies. Studies that measured leukocytes/
CD45 + cells (n = 5), granulocytes (n = 4), lympho-
cytes (n = 3) or macrophages (n = 3) showed a decrease 
or no change in these cell subsets. Looking further 
into the lymphocytes, the direction of the effect on 
CD3 + (n = − 3), CD4 + (n = 6), and CD8 + T cells (n = 4) 
and B220 B cells (n = 5) varied per study. The effect for 
the different cell types in general had the same direction, 
so when no effect was seen in CD4 + cells, also no effect 
was seen in CD8 + T cells and B220 cells. It has to be 
taken into account that for the summary of this data no 
differentiation was made between absolute cell numbers 
or percentages or between the methods of measurement 
(e.g. FACS/IHC etc.).
Seventeen studies looked at one or more cytokines. 
Most studies found reduced numbers or percentages of 
cytokines. Two studies showed no changes in any of the 
measured cytokines.
Table  3 shows a summary of data without differen-
tiation between numbers/percentages and methods of 
measuring (e.g. FACS, ELISA/Luminex, qPCR). The pro-
inflammatory cytokine IL-1β was measured in 7 stud-
ies. Five studies found lowered numbers/percentages of 
IL-1β, while 2 studies found no effect. The Th1-associated 
cytokines IL-12, IFN-γ and TNFα were lower in general. 
TNFα was measured in most studies, 11 in total. Eight 
studies showed lower TNFα levels, 2 showed no change 
and 1 study showed an increase. The Th2 associated 
cytokines IL-4, IL-5 and IL-13 were only measured in 3, 
2 and 2 studies respectively. One study showed no effect 
Fig. 3 Reporting of quality indicators in the included studies. The following questions were asked: (1) Is any blinding reported? (2) Is any 
randomization reported? (3) Is the sample size calculation reported? (4) Are housing conditions reported? (5) Is ethical approval reported? (6) Are 
any conflicts of interest reported?
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on IL-4, the other studies showed a decrease in IL-4 and 
the other Th2 cytokines. The Th17 associated cytokines 
TGFβ, IL-6 and IL-17 were studied in 1, 7 and 6 studies 
respectively. All cytokines were equal of lower compared 
to control.
The anti-inflammatory cytokine IL-10 was studied in 
6 studies. 3 studies found no effect on IL-10 production. 
In these 3 studies also no effect on the pro-inflammatory 
cytokines was found, except for lowered IL-17 levels in 
one study. One study found an increase in IL-10 and 1 
found a decrease in IL-10. One study used targeted deliv-
ery of Aza, using nanolipogels (nlg). In this study Aza-nlg 
lowered all cytokines including IL-10 compared to empty 
nlg.
Discussion
Inflammatory disorders like diabetes [65], SLE [41], 
inflammatory lung diseases [48, 49], RA [57] and MS 
[60], but also rejection of transplanted organs [31] and 
GvHD [32] have a major effect on mortality, morbidity 
and costs of health care. These disorders have in com-
mon that they are often treated with immune suppres-
sive drugs. Current classes of immune suppressive drugs 
never completely inhibit the inflammation and adverse 
side effects are common. Therefore there is a need for 
new drugs with other working mechanisms. Potential 
candidates are the DNMTi’s Aza and DAC [12, 21, 66]. 
Aza and DAC have been tested in several pre-clinical 
in vivo studies. In order to obtain an overview of disor-
ders where Aza and/or DAC can be a potential treatment 
and to find out where information is lacking we systemat-
ically reviewed pre-clinical animal studies assessing Aza 
or DAC as a potential therapy for different inflammatory 
disorders.
Our review provides evidence that pre-clinically tested 
therapies seem to alleviate several inflammatory disor-
ders. It is interesting to see that despite the large differ-
ences in diseases, disease models and treatment regimen, 
the overall conclusion is very similar. We show that Aza 
and DAC can improve health outcome in models for 
GvHD, organ rejection, diabetes, atherosclerosis, BA, 
SLE, vitiligo, ARDS, asthma, RA, MS and GBS.
Aza was developed in the sixties by the group of Ves-
ely and Cihak as a cancerostatic drug [67]. In the eight-
ies it was discovered by the same group that Aza has 
immune inhibitory effects when used in lower doses. 
Aza/DAC are used to treat hematological malignancies, 
with or without transplantation of stem cells. It therefore 
makes sense that the immune modulatory effect of Aza/
DAC is most often studied in GvHD and the prevention 
of organ rejection. In the nineteen-eighties, Paluska et al. 
[19] and Sula et al. [68] (both from the group of Cihak), 
described for the first time that Aza and DAC have both 
immunosuppressive and immune stimulatory effects 
on allogeneic splenocyte induced GvHD. The effect was 
dependent on the dose and timing of Aza and DAC 
administration. More recent studies [21, 69–71] induced 
GvHD in mice by injecting bone-marrow derived stem 
cells (SCT) and allogeneic (Treg depleted) T cells in 
lethally irradiated mice. Aza/DAC was administered 
after SCT. Mice treated with Aza or DAC had increased 
survival rates and less signs of GvHD related symptoms. 
Cooper et  al. showed that this effect of Aza was Treg 
dependent, using Treg depletion experiments [71].
The effect of Aza/DAC on organ rejection was stud-
ied with different organ transplantation models. Mice or 
rats were transplanted with skin [19], cardiac allograft 
[26–28], hematopoietic stem cell (HSC) [72] or pancre-
atic islets [30]. In the studies addressing the research 
question what the effect of Aza/DAC was on organ rejec-
tion, Aza/DAC was shown to prolong graft survival [19, 
27–29]. However, in studies that examined whether 
Treg or Aza + rapamycin could prevent organ rejection, 
it appeared that treatment with Aza-treated Treg or 
monotreatment with Aza did not prolong graft survival. 
The latter two studies used Aza while the other studies 
(except Paluska et  al., who used both) used DAC, how-
ever it cannot be concluded that the difference is due to 
the difference in Aza/DAC. Also, different doses and dos-
ing regimen where used.
Five studies on diabetes were published [34–38], using 
4 different mouse models. The STZ and CY-NOD mod-
els are used to study T1DM, while the db/db and ob/ob 
models are suited to study T2DM. The focus of the differ-
ent studies was on insulin sensitivity, the effect on mac-
rophage polarization and on diabetic nephropathy. The 
heterogeneity between the studies on seemingly the same 
subject is so large that it was not possible to make a good 
comparison. Still, except for the study of Gao et  al., all 
studies showed improved clinical outcome. In the study 
of Gao, MSC in combination with DAC improved clinical 
outcome. DAC alone did not.
For ARDS the methodology used was more compa-
rable. The disease is induced in mice by either injection 
or inhalation of LPS. Three studies show that a dose of 
1  mg/kg of either Aza or DAC is effective in alleviating 
lung injury, either when injected 1 h before [50], 1 h after 
[51], or with repeated dosing of LPS [52]. In the 2 stud-
ies by Thangavel et al. a lethal dose of LPS was used. Aza 
alone did not increase survival, however in combina-
tion with Trichostatin A (TSA) a significant increase in 
survival was seen [73, 74]. In the second study a dose of 
1 mg/kg was used like in the other ARDS studies.
For this systematic review we studied non-infectious 
inflammation including auto-immune and auto-inflam-
matory disorders, organ rejection after transplantation 
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and GvHD. What these diseases have in common is that 
the immune system is over active and that the body is 
attacking its own tissues or the transplanted organ. Com-
mon treatment for these diseases is immunosuppression, 
often by suppressing T cells. It is very difficult, if not 
impossible, to make a comparison between the different 
diseases since the diseases are so divers.
The choice to measure which clinical outcome, but 
also which immune cells and which cytokines are 
mainly dependent on the specific disease and also on 
the hypothesis for the working mechanism of Aza/DAC. 
Inflammatory disorders can be roughly divided into Th1, 
Th2 and Th17 driven diseases. Unfortunately, not enough 
data on cells subsets and cytokine production are avail-
able to group results from the different diseases from the 
papers that we reviewed. Mainly, disease specific clini-
cal outcome measures are shown for example. Studies 
about asthma will not show the effect on joint swelling, 
vice versa RA studies RA will not show results on lung 
inflammation.
When looking at the hypothesis, an interesting obser-
vation is that the hypothesis about the mechanism 
through which Aza/DAC could prevent or treat the dif-
ferent disorders varies widely among the studies. Four-
teen studies hypothesized that induction of FOXP3, 
causing an increase in Treg, is the mechanism through 
which Aza/Dac can be used as a potential treatment for 
the different immune disorders. Seventeen studies meas-
ured FOXP3 and/or Treg, of which indeed most found an 
increase in FOXP3/Treg. Three studies hypothesized that 
a change in regulation of effector T cells/the Th1/Th2 
balance [21, 56, 64] is affected by DNMTi, 3 mention a 
change in macrophage polarization [35, 36, 54], 1 study 
mentions a change in differentiation of CD34 + stem 
cells [29], 1 study regulation of neutrophil apoptosis by 
modulating DAPK1 expression [51] and 1 mentions a 
change in B-cells [59]. The remaining studies hypothesize 
that hypomethylation leads to an effect on specific tar-
get cells like podocytes [34] or lung epithelial cells [53] 
or just mention regulation by DNMTi’s in general. This 
also results in a wide variety of results that are described. 
Beside Treg, 18 studies in total mention changes in leuko-
cytes, granulocytes, lymphocytes, macrophages, CD3−, 
CD4−, CD8− and B220 cells. This means that despite 
that the fact that all these studies are about immune dis-
orders, 12 studies do not mention changes in the major 
subsets of immune cells. Like the immune cell subsets, 
the different cytokines are only mentioned in a few stud-
ies. One or more cytokines were measured in 17 studies. 
In general cytokine production is lower, except for IL-10, 
where contradictory results are found between studies 
and disorders. None of the studies describe mechanis-
tically why cytokine levels change. The low number of 
studies describing cytokines prohibits conclusion on the 
effect of Aza/DAC on cytokine production.
Despite the differences in disease mechanism, hypoth-
esis on the working mechanism and the differences in 
treatment, the effect on clinical outcome is very similar. 
Overall, in 31 out of the 35 included studies clinical out-
come improved, while in 4 no effect was found. None on 
the studies showed that Aza/DAC deteriorated the dis-
ease. An important conclusion is that the effect of Aza 
and DAC seems to be dependent on the concentration 
that is used. A few studies tested different concentrations 
and saw that the effect was dose dependent. Beside differ-
ent concentrations, also different dosing regimens were 
used. Most studies use multiple dosing, some start before 
the induction of the disorder (prevention protocol), while 
others start treating after the start/induction of the dis-
order (treatment protocol). Also a combination of treat-
ment before and after induction is seen. In 4 of the ARDS 
studies a single dose of Aza/DAC is used. Because of the 
differences in dosing regimen it is not possible to draw 
a conclusion on which concentration is optimal, even 
though this is tested in several studies.
The different studies describe limited or no side effects 
in the animals treated with Aza/DAC. However, several 
studies also describe that Aza can induce the immune 
disease SLE in mice [42, 43] and vitiligo in chickens[47]. 
In these studies different strains were used, indicating 
that genetic background plays an important role in the 
outcome of the treatment. In human Aza/DAC are well-
tolerated and side effects like induction of SLE or vitiligo 
are not seen.
Limitations
Inflammatory disorders form a broad spectrum of dis-
orders and conclusions on the effect of Aza/DAC in a 
given disorder should not be drawn based on the out-
come in another. For every disease only a limited number 
of studies was found. The heterogeneity in experimental 
approach both within and between diseases was substan-
tial. Dosing and dosing schedule were not comparable 
between different studies. Taken together, this did not 
allow for a meta-analysis. Therefore, the interpretation 
of the results had to be based on the results as reported 
by the authors and the effect size could not be taken into 
account. Also, some studies used a prevention protocol 
while others used a treatment protocol. Except for organ 
transplantation/GvHD a preventive protocol is often not 
possible. This limits the possibility to translate the study 
to the human situation.
Like in many other systematic reviews of animal stud-
ies, an important limitation of this review is that many 
of the essential methodological details of animal studies 
included in our review were poorly reported [75]. This 
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directly affects the reliability of the conclusions based on 
those studies and hampers a reliable risk of bias assess-
ment. Despite the fact that we cannot reliably estimate 
how internally valid the results are, we included all papers 
that met the criteria, since poor reporting does not nec-
essarily mean impaired methodology. Poor reporting 
emphasizes the fact that reporting should be improved 
for future studies by reporting more essential details, as 
described for example in the ARRIVE guidelines [76], as 
it can only increase the reliability of a study.
The limited data available also did not allow for an eval-
uation of publication bias. It is, however, remarkable that 
studies studying a combination of Aza/DAC with another 
therapy found no effect for Aza/DAC single treatment, 
while the studies that primarily studied the effect of Aza/
DAC on the disease always found an improved clinical 
outcome.
Another important thing to take into account when 
interpreting the results is that very divergent data are 
displayed. For example, the absolute number of cells may 
decrease, but the percentage of cells may increase. Also 
results from for example qPCR and ELISA/Luminex can 
differ in effect size. In Tables  2 and 3 we combined all 
data without looking at the method of measurement or 
the derived quantity. It is difficult to say what the most 
important or most reliable outcome measure is. Describ-
ing both changes in absolute numbers and changes in 
percentages would be optimal. What method is best, 
depends on the exact research question.
Clinical relevance and recommendations
Aza and DAC are currently used for the treatment of 
myelodysplastic diseases such as AML and MDS [5, 6]. 
Clinical studies are already done to test whether Aza/
DAC may also improve stem cell transplantation in these 
diseases [77–80]. To our knowledge, no clinical stud-
ies are done to assess whether Aza/DAC can be used to 
prevent GvHD or rejection of transplanted organs or as a 
treatment for diabetes, atherosclerosis, BA, SLE, vitiligo, 
ARDS, asthma, RA, MS or GBS. Based on the results of 
our review, GvHD/organ transplantation and inflamma-
tory lung diseases seem interesting candidates for clini-
cal studies. However, conclusions from this review are 
based on limited data and should therefore be used with 
caution.
Aza is already used in hematological malignancies. 
Therefore it can be considered safe in humans. A big 
challenge will be to apply the best dose. More experi-
ments in animals can help to optimize the design for a 
clinical study. For clinical studies it is important to have 
biomarkers that can be measured to assess the result of 
the therapy, preferably a marker that can be measured in 
blood. We therefore recommend that for future animal 
studies using Aza/DAC to treat inflammatory disease, 
more immune related outcomes, such as changes in cell 
subsets and cytokines are being measured. Following 
this, it would be very useful to investigate whether for 
these biomarkers the results of the pre-clinical studies are 
in line with future clinical studies.
Conclusions
Aza and DAC seem to be promising candidates for the 
therapy of different inflammatory disorders. Increased 
Treg numbers seems to be the common ground for this 
effect. Based on these results it is too early to start clini-
cal studies. Improving the reporting and methodological 
quality of animal studies can help to advance the transi-
tion to clinical studies. Further pre-clinical studies should 
include more biomarkers, such as immune cells sub-
sets and cytokines, this will facilitate the step to clinical 
studies.
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